A clinical research trial is an important step towards finding potential future treatments for people with aPAP. If you decide to take part, you’ll be helping researchers and physicians understand this rare disease better and could, potentially, play an important role in improving healthcare for other people living with aPAP.
Why we’re doing this research
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease with no approved pharmacologic treatment options. The disease is characterized by the build-up of surfactant in the alveoli (air sacs) of the lungs leading to impaired oxygen transfer from the lungs to the blood.
People with aPAP may experience symptoms like shortness of breath and a decreased ability to exercise. Typically, shortness of breath is first observed upon exertion, but as the disease progresses, shortness of breath can be experienced even when a person is at rest. Cough, as well as episodes of fever, can also be experienced especially if secondary lung infection develops. In the long-term, the disease can lead to serious complications, including lung fibrosis and the need for lung transplant.
Details on the IMPALA-2 aPAP clinical trial
This clinical research trial is being carried out to discover whether molgramostim nebulizer solution:
- Is safe to take
- Can help to reduce the symptoms of aPAP